Roger Stupp, MD, Professor of Oncology, University of Zürich; Chairman, Department of Oncology and Cancer Center, University of Zürich Hospital, Zürich, Switzerland, discusses the interim analysis of the EF-14 trial, which compared NovoTTF-100A together with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM).
NovoTTF, also known as Optune, creates tumor treating fields (TTFields) that interfere with cell division at different phases of mitosis. The phase III EF-14 trial is the second prospective study to demonstrate the efficacy of the NovoTTF in GBM. Previous studies looked at the treatment in patients with recurrent GBM while EF-14 examined the device in newly diagnosed patients, Stupp says.
In the EF-14 trial, 700 patients were enrolled and the first 315 patients were analyzed. Stupp says patients that were treated with NovoTTF plus temozolomide demonstrated an improvement in progression-free survival compared with temozolomide alone (median PFS of 7.1 months compared with 4.0 months, respectively; HR = 0.63, P
= .001). Overall survival was extended by 3 months with NovoTFF, with a median OS of 19.6 months compared to 16.6 months with tomozolomide alone (HR = 0.75, P
<<< View more from the 2014 Society for Neuro-Oncology Annual Meeting